Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, announced results from a long-term (52-week) phase III trial of OTEZLA, the company’s oral, selective inhibitor of phosphodiesterase 4 (PDE4), in psoriatic arthritis patients who have not had prior treatment with systemic or biologic disease-modifying antirheumatic drugs (DMARDs). The data were presented at the European League Against Rheumatism Annual Congress (EULAR 2014) in Paris, France.
“Physicians need a variety of options to treat psoriatic arthritis, as treatment is highly individualised and some patients may not be appropriate candidates for biologics or certain systemic therapies,” said Alvin Wells, Director, Rheumatology and Immunology Center, Franklin, MN. “These efficacy and safety results suggest that OTEZLA monotherapy has the potential to be used for adults with active psoriatic arthritis in the first-line setting, prior to the initiation of DMARD therapy, and possibly as a long-term treatment option.”
EP News Bureau – Mumbai